Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OvaRex in Ovarian Cancer Patients With Elevated CA 125
NCT00004064Phase 2Unknown
- Sponsor
- AltaRex Medical
- Start
- Nov 1998
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AltaRex Medical. Status: unknown.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00004064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004064.